临床合理用药杂志
臨床閤理用藥雜誌
림상합리용약잡지
CHINESE JOURNAL OF CLINICAL RATIONAL DRUG USE
2015年
5期
18-19,21
,共3页
TM-Gp方案%Gp方案%非小细胞肺癌%临床药学研究
TM-Gp方案%Gp方案%非小細胞肺癌%臨床藥學研究
TM-Gp방안%Gp방안%비소세포폐암%림상약학연구
TM-Gp scheme%Gp%Non-small cell lung cancer%Clinical pharmaceutical research
目的：研究 TM_Gp 方案（胸腺五肽；甲地孕酮；吉西他滨；顺铂）与 Gp 方案（吉西他滨；顺铂）对初治Ⅲ_Ⅳ期 NSCLC（非小细胞肺癌）患者的疗效、毒性反应及生活质量的改善情况。方法所有选取的病例按肿瘤多学科联合会诊制度及流程确定。A 组（33例）接受 TM_Gp 方案治疗；B 组（35例）接受 Gp 方案治疗。2组均以4周为1周期，重复3个周期。客观疗效与毒性反应按市、县级医院常见肿瘤规范化诊疗指南（试行）》标准进行评价，生活质量根据临床受益疗效来评价。结果客观疗效（CR ﹢ pR）：A 组为27,3％；B 组为22,9％（p ＞0,05）；中位生存期：A组32周，B 组27周（p ＜0,01）；白细胞减少及恶心呕吐反应 B 组均较 A 组明显（p ＜0,01）；短暂性寒战、发热症状多见于 A 组（p ＜0,01）；2组均未发现其他严重的不良反应。A 组行为状态阳性率45,4％，B 组行为状态阳性率20,0％（p ＜0,05）。A 组体质量阳性率30,3％；B 组体质量阳性率11,4％（p ＜0,05）。A 组临床受益疗效高于 B 组（p ＜0,05）。结论 TM_Gp 方案与 Gp 方案客观疗效无明显差异性；TM_Gp 联合方案中位生存期长，不良反应小，生活质量改善明显。
目的：研究 TM_Gp 方案（胸腺五肽；甲地孕酮；吉西他濱；順鉑）與 Gp 方案（吉西他濱；順鉑）對初治Ⅲ_Ⅳ期 NSCLC（非小細胞肺癌）患者的療效、毒性反應及生活質量的改善情況。方法所有選取的病例按腫瘤多學科聯閤會診製度及流程確定。A 組（33例）接受 TM_Gp 方案治療；B 組（35例）接受 Gp 方案治療。2組均以4週為1週期，重複3箇週期。客觀療效與毒性反應按市、縣級醫院常見腫瘤規範化診療指南（試行）》標準進行評價，生活質量根據臨床受益療效來評價。結果客觀療效（CR ﹢ pR）：A 組為27,3％；B 組為22,9％（p ＞0,05）；中位生存期：A組32週，B 組27週（p ＜0,01）；白細胞減少及噁心嘔吐反應 B 組均較 A 組明顯（p ＜0,01）；短暫性寒戰、髮熱癥狀多見于 A 組（p ＜0,01）；2組均未髮現其他嚴重的不良反應。A 組行為狀態暘性率45,4％，B 組行為狀態暘性率20,0％（p ＜0,05）。A 組體質量暘性率30,3％；B 組體質量暘性率11,4％（p ＜0,05）。A 組臨床受益療效高于 B 組（p ＜0,05）。結論 TM_Gp 方案與 Gp 方案客觀療效無明顯差異性；TM_Gp 聯閤方案中位生存期長，不良反應小，生活質量改善明顯。
목적：연구 TM_Gp 방안（흉선오태；갑지잉동；길서타빈；순박）여 Gp 방안（길서타빈；순박）대초치Ⅲ_Ⅳ기 NSCLC（비소세포폐암）환자적료효、독성반응급생활질량적개선정황。방법소유선취적병례안종류다학과연합회진제도급류정학정。A 조（33례）접수 TM_Gp 방안치료；B 조（35례）접수 Gp 방안치료。2조균이4주위1주기，중복3개주기。객관료효여독성반응안시、현급의원상견종류규범화진료지남（시행）》표준진행평개，생활질량근거림상수익료효래평개。결과객관료효（CR ﹢ pR）：A 조위27,3％；B 조위22,9％（p ＞0,05）；중위생존기：A조32주，B 조27주（p ＜0,01）；백세포감소급악심구토반응 B 조균교 A 조명현（p ＜0,01）；단잠성한전、발열증상다견우 A 조（p ＜0,01）；2조균미발현기타엄중적불량반응。A 조행위상태양성솔45,4％，B 조행위상태양성솔20,0％（p ＜0,05）。A 조체질량양성솔30,3％；B 조체질량양성솔11,4％（p ＜0,05）。A 조림상수익료효고우 B 조（p ＜0,05）。결론 TM_Gp 방안여 Gp 방안객관료효무명현차이성；TM_Gp 연합방안중위생존기장，불량반응소，생활질량개선명현。
Objective To study the efficacy,reactions of toxic and improvement of life quality of TM_Gp scheme (thymopentin megestrol;megestrol;gemcitabine;and cisplatin)and Gp(gemcitabine and cisplatin)on initial Ⅲ _ Ⅳ NSCLC (non_small cell lung cancer)patients, Methods All cases were collected according to tumor multidisciplinary joint consulta_tion system and process, Group A(n = 33)received TM_Gp solution for treatment;the Group B(n = 35)received Gp solution for treatment, Both groups were treated with 4 weeks as 1 cycle,with repeating 3 cycles, Objective curative effect and toxicity were evaluated according to the municipal,county_level hospitals common tumor standardized guidelines(try out)standard, The quality of life was assessed according to the clinical benefit response, Results The objective curative effect(CR ﹢ pR):group A was 27, 3% ;group B was 22, 9%(p > 0, 05);The median survival:group A was 32 weeks,while the group B was 27 weeks(p < 0, 01);In the matter of leukopenia,nausea and vomiting response,the group A was better than group B significant (p < 0, 01);The transient chills,fever symptoms were more common in the A group(p < 0, 01);Both groups were not found other serious toxicity reaction, The behavior state positive rate of group A was 45, 4% ,while the group B was 20, 0% ;(p <0, 05), The body weight positive rate of group A were 30, 3% ,while the group B was 11, 4% ;(p < 0, 05), The clinical benefit response of group was higher than group B(p < 0, 05), Conclusion There is no obvious difference in curative effect between TM_Gp solutions andd Gp;The median survival period of TM_Gp is long,with smaller side reaction,and the quality of life of which improved significantly.
